Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 500.00% and -7.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and 3.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Vanda (VNDA) Q4 Earnings: What's in Store for the Stock
by Zacks Equity Research
On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
by Zacks Equity Research
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential
by Zacks Equity Research
Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential
5 Stocks With Recent Price Strength Despite Volatile Market
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
by Zacks Equity Research
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
by Zacks Equity Research
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
by Zacks Equity Research
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
by Zacks Equity Research
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty
by Madhura Bhattacharyya
Let's take a look at seven growth stocks that are poised to offer impressive returns in 2019.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
4 Stocks That Had Massive Earnings Surprises in 2018
by Ankita Gupta
Given the market volatility, let's take a look at four stocks that survived the onslaught and even surpassed market expectations.
Inovio (INO) to Receive Milestone Payment From AstraZeneca
by Zacks Equity Research
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Amgen's BiTE Immunotherapies Show Promise in Early Studies
by Zacks Equity Research
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
Company News For Dec 4, 2018
by Zacks Equity Research
Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT